Actavia Life Sciences, Inc. (RASP) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Actavia Life Sciences, Inc. (RASP) es una empresa del sector Healthcare valorada en 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Actavia Life Sciences, Inc. (RASP) Resumen de Asistencia Médica y Tuberías
Actavia Life Sciences, Inc., a biotechnology firm, focuses on developing therapeutics for leukemia and lymphoma, particularly small molecule drug candidates for acute myeloid leukemia. Operating in the competitive biotechnology sector, the company navigates the high-risk, high-reward landscape of drug development with a focus on hematological malignancies.
Tesis de Inversión
Actavia Life Sciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing therapeutics for leukemia and lymphoma, particularly AML, addresses a significant unmet medical need. However, as of 2026-03-16, the company's market capitalization is $0.00B, and it operates with a single employee, indicating an early stage of development. A negative P/E ratio of -0.07 suggests the company is not currently profitable. The company's success hinges on its ability to advance its drug candidates through preclinical and clinical development, secure regulatory approvals, and ultimately commercialize its therapies. Investors should carefully consider the inherent risks associated with biotechnology investments, including the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.00B, indicating a micro-cap company.
- P/E ratio of -0.07, reflecting current lack of profitability.
- Beta of -64.36, suggesting an inverse correlation with the market, but should be interpreted with caution due to the company's size and stage.
- Focus on developing therapeutics for leukemia and lymphoma, addressing a significant unmet medical need.
- Operates with a single employee, indicating a very early stage of development and high reliance on external resources.
Competidores y Pares
Fortalezas
- Focus on a specific therapeutic area (leukemia and lymphoma).
- Development of small molecule drug candidates.
- Potential for novel therapies to address unmet medical needs.
- Location in New York City, providing access to talent and resources.
Debilidades
- Early stage of development with limited resources (one employee).
- Lack of revenue and profitability.
- High dependence on external funding.
- Significant regulatory and clinical development risks.
Catalizadores
- Upcoming: Announcement of preclinical data for AML drug candidates.
- Upcoming: Initiation of Phase 1 clinical trial for lead drug candidate.
- Ongoing: Pursuit of strategic partnerships and collaborations.
- Ongoing: Efforts to secure additional funding and investment.
- Ongoing: Research and development activities to expand pipeline.
Riesgos
- Potential: Clinical trial failures and setbacks.
- Potential: Regulatory hurdles and delays.
- Potential: Competition from established pharmaceutical companies.
- Potential: Inability to secure sufficient funding.
- Ongoing: Limited resources and operational capacity due to small size.
Oportunidades de crecimiento
- Advancement of AML drug candidates: Actavia's primary growth opportunity lies in the successful development and commercialization of its small molecule drug candidates targeting acute myeloid leukemia. The global AML market is projected to reach billions of dollars, offering significant revenue potential for Actavia if its therapies prove effective and safe. Timeline: Ongoing, with preclinical and clinical milestones to be achieved.
- Expansion into other hematological malignancies: Actavia could expand its pipeline to include therapeutics for other hematological malignancies beyond leukemia and lymphoma. This would broaden its addressable market and diversify its product portfolio. Timeline: Potential expansion within the next 3-5 years, contingent on successful advancement of current pipeline.
- Strategic partnerships and collaborations: Actavia could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. This would provide access to additional funding, expertise, and resources. Timeline: Ongoing, with potential partnerships to be formed as pipeline progresses.
- Out-licensing of drug candidates: Actavia could out-license its drug candidates to other companies for further development and commercialization. This would generate upfront and milestone payments, as well as royalties on future sales. Timeline: Potential out-licensing opportunities as pipeline progresses and clinical data becomes available.
- Acquisition by a larger pharmaceutical company: Actavia could be acquired by a larger pharmaceutical company seeking to expand its oncology pipeline. This would provide a significant return on investment for Actavia's shareholders. Timeline: Potential acquisition within the next 5-7 years, contingent on successful pipeline development and clinical data.
Oportunidades
- Advancement of drug candidates through clinical trials.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into other hematological malignancies.
- Out-licensing of drug candidates.
Amenazas
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Inability to secure sufficient funding.
Ventajas competitivas
- Intellectual property protection (patents) on novel drug candidates.
- Proprietary knowledge and expertise in drug discovery and development.
- Potential for orphan drug designation, providing market exclusivity.
- First-mover advantage in developing novel therapies for specific subtypes of leukemia and lymphoma.
Acerca de RASP
Founded in 2013 and headquartered in New York City, Actavia Life Sciences, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics for the treatment of leukemia and lymphoma. The company's primary focus is on developing small molecule drug candidates that target acute myeloid leukemia (AML), a particularly aggressive form of blood cancer. Actavia's research and development efforts are centered on identifying and validating promising drug targets and advancing preclinical candidates towards clinical trials. As a biotechnology company, Actavia operates within a complex and highly regulated environment, requiring significant investment in research, development, and clinical testing to bring its therapies to market. The company's success depends on its ability to successfully navigate the drug development process, secure regulatory approvals, and ultimately commercialize its products.
Qué hacen
- Develops therapeutics for the treatment of leukemia and lymphoma diseases.
- Focuses on small molecule drug candidates.
- Targets acute myeloid leukemia (AML).
- Conducts research and development activities.
- Seeks to identify and validate promising drug targets.
- Advances preclinical candidates towards clinical trials.
Modelo de Negocio
- Develops and patents novel therapeutic compounds.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval from agencies such as the FDA.
- May out-license or partner with larger pharmaceutical companies for commercialization.
Contexto de la Industria
Actavia Life Sciences, Inc. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and significant regulatory oversight. The market for leukemia and lymphoma therapeutics is substantial, driven by the prevalence of these diseases and the ongoing need for more effective treatments. Actavia competes with both established pharmaceutical companies and other biotechnology firms in the development of novel therapies. The company's success depends on its ability to differentiate its drug candidates, secure intellectual property protection, and navigate the complex regulatory landscape.
Clientes Clave
- Patients suffering from leukemia and lymphoma.
- Healthcare providers who treat these patients.
- Pharmaceutical companies interested in licensing or acquiring novel therapeutics.
Finanzas
Gráfico e información
Precio de la acción de Actavia Life Sciences, Inc. (RASP): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para RASP.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para RASP.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para RASP.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de RASP en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Keeren Shah
CEO
Keeren Shah is the CEO of Actavia Life Sciences, Inc. Details regarding Keeren Shah's prior experience and educational background are not available in the provided data. As the leader of a biotechnology company focused on developing therapeutics for leukemia and lymphoma, Keeren Shah's expertise likely includes areas such as drug development, oncology, and business strategy. The success of Actavia Life Sciences depends heavily on Keeren Shah's ability to navigate the complex biotechnology landscape and secure funding.
Historial: As of 2026-03-16, Actavia Life Sciences, Inc. is in an early stage of development, with a market capitalization of $0.00B and only one employee. Key milestones under Keeren Shah's leadership would include advancing drug candidates through preclinical and clinical development, securing regulatory approvals, and establishing strategic partnerships. However, specific achievements and strategic decisions are not detailed in the provided data.
Información del mercado OTC de RASP
The OTC Other tier, where Actavia Life Sciences trades, represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet minimum listing standards. This tier is generally considered to be the most speculative and carries the highest risk due to the potential for limited information and regulatory oversight. Companies in this tier may be newly formed, financially distressed, or have chosen not to meet the stricter requirements of higher-tier exchanges. Investing in OTC Other stocks requires a high degree of due diligence and risk tolerance.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of company failure or delisting.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Attempt to obtain audited financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with the company's industry and operations.
- Consult with a qualified financial advisor.
- Be prepared to lose your entire investment.
- Company has been in operation since 2013.
- Focus on developing therapeutics for a specific disease area (leukemia and lymphoma).
- Headquartered in New York City.
- Presence of a CEO (Keeren Shah).
RASP Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar RASP?
Actavia Life Sciences, Inc. (RASP) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Focus on a specific therapeutic area (leukemia and lymphoma).. Riesgo principal a monitorear: Potential: Clinical trial failures and setbacks.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de RASP?
RASP actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de RASP?
Los precios de RASP se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre RASP?
La cobertura de analistas para RASP incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en RASP?
Las categorías de riesgo para RASP incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures and setbacks.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de RASP?
La relación P/E para RASP compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está RASP sobrevalorada o infravalorada?
Determinar si Actavia Life Sciences, Inc. (RASP) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de RASP?
Actavia Life Sciences, Inc. (RASP) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available for Actavia Life Sciences, Inc.
- OTC market carries higher risks than major exchanges.
- Financial data is limited and may not be up-to-date.